CBIS News just Out - Cannabis Science Updates Second Medical Cannabis Cancer Patient Suffering from Squamous Cell Carcinoma Photo-documents Cannabis Extracts Killing Cancerous Tumor
Business Wire "Press Releases - English"
Cannabis Science, Inc. (OTCBB: CBIS) a pioneering U.S. biotech company
developing pharmaceutical cannabis (marijuana) products, is very pleased
to announce that the second patient suffering from basal cell carcinoma
(skin cancer) has self-administered cannabis extracts that appear to
have eradicated the cancer.
Following up on the December 12, 2011 news release regarding a second
cancer patient self-administering cannabis extract, this patient has now
given the photo-documented dramatic results of treatment process. These
images can be viewed on the www.cannabisscience.com
website. While the treatment has been completed and the cancer seems to
be gone, Cannabis Science is waiting for a full biopsy report from the
physician to confirm the patient is free of cancer cells.
Currently it appears that the aforementioned patient will be able to
avoid any surgical procedures such as, standard surgical excision (Mohs
Surgery), and other various types of treatment for skin cancer, like
chemotherapy, radiation, and cryosurgery, by using the cannabis
extracts, just like the first patient mentioned in our March 9, 2011
While other treatment options may be effective for many, few patients
would choose to go through a surgical procedure, and endure the side
effects of radiation, or chemotherapy if a simpler and safer alternative
were available. Patients self-administering cannabis extracts in the
convenience of their own home appear to be effectively resolving their
cancerous lesions over a period of a few weeks to a few months.
Cannabis Science is committed to making cannabis-based medicines
available to the public as rapidly as possible. The Company is taking
multiple approaches to accomplishing this aim in the United States. The
science of cannabinoids has exploded over the past decade, laying the
scientific foundation for the many medicinal uses of this unique plant.
Endoannabinoids are a class of biologically active lipid compounds
produced by all vertebrates (endocannabinoids) the Cannabis plant
(phytocannabinoids), and more recently patentable synthetic compounds
produced by chemists. Todays modern peer-reviewed science supports the
many historical uses that were discovered over thousands of years of
medicinal use by herbalists.
Please visit www.cannabisscience.com
to view the Breaking News of the successful results and images of the
self-administered cancer treatments.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade
medical marijuana research and development. The second formulations will
address the needs of patients choosing to use concentrated cannabis
extracts to treat their ailments. Eventually, all Americans will have
access to a safe and effective FDA approved medicine regardless of which
state they live in. To maintain that marijuana is a dangerous, addictive
drug with no medical value is scientifically absurd. Cannabis medicines,
with no effective lethal dose, are far safer than aspirin,
acetaminophen, and most other OTC drugs that kill thousands of Americans
The Company works with world authorities on phytocannabinoid science
targeting critical illnesses, and adheres to scientific methodologies to
develop, produce and commercialize phytocannabinoid-based pharmaceutical
products. In sum, we are dedicated to the creation of cannabis-based
medicines, both with and without psychoactive properties, to treat
disease and the symptoms of disease, as well as for general health
Forward Looking Statements
This Press Release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Act of 1934. A statement containing works such as
"anticipate," "seek," intend," "believe," "plan," "estimate," "expect,"
"project," "plan," or similar phrases may be deemed "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Some or all of the events or results anticipated by
these forward-looking statements may not occur. Factors that could cause
or contribute to such differences include the future U.S. and global
economies, the impact of competition, and the Company's reliance on
existing regulations regarding the use and development of cannabis-based
drugs. Cannabis Science, Inc. does not undertake any duty nor does it
intend to update the results of these forward-looking statements.
Cannabis Science Inc.
Dr. Robert J. Melamede, 1-888-889-0888